Our results demonstrated that ERCC6 knockdown significantly increased cisplatin sensitivity, reduced proliferation, promoted apoptosis, and suppressed tumor growth in both in vitro and in vivo osteosarcoma models. This evidence concerns the gene ERCC6 and neoplasm.